Navigation Links
LoneStar Heart Inc. Names Andrew J. Coats, M.D., and Mark Maciejewski to Its Board of Directors
Date:1/24/2012

LAGUNA HILLS, Calif., Jan. 24, 2012 /PRNewswire/ -- LoneStar Heart Inc., based here, today announced that it has elected Andrew J. Coats, M.D., and Mark Maciejewski to the company's board of directors. The new members join Olav B. Bergheim, chairman of the board for LoneStar Heart; Frank Ahmann, the company's president and chief oper­ating officer; Raymond W. Cohen, chief executive officer of Vessix Vascular, Inc.; and Eric N. Olson, Ph.D., professor and chairman of the department of molecular biology at the University of Texas Southwestern Medical Center at Dallas (UTSW), and LoneStar Heart's scientific co-founder and board observer.

"Dr. Coats is a renowned medical researcher, practitioner, and world-class busi­ness professional in the field of cardiac medicine," said Olav B. Bergheim, chairman of LoneStar Heart. "Together with Mark Maciejewski's broad expertise in developing Asian medical markets, their high caliber of experience and leadership will be invaluable as LoneStar Heart advances its broad portfolio of products to treat heart failure."

Dr. Coats, 53, is a scientific founder and founding board member of Myotec Therapeutics Ltd. He trained in medicine at the Universities of Oxford and Cambridge, and holds higher doctorates from Oxford and Imperial College, and an M.B.A. from the London Business School. He was the first Viscount Royston Professor at the National Heart and Lung Institute, becoming director of cardiology at the Royal Brompton Hospital, and then associate medical director of the Royal Brompton and Harefield NHS Trust. He was then dean of medicine at the University of Sydney, becoming deputy vice chancellor in 2006. He is editor-in-chief of the International Journal of Cardiology and has more than 1,000 publications, including 450 full papers in peer-reviewed journals and more than 35,000 career citations. Dr. Coats has served as the chairman or steer­ing committee member for many major morbidity/mortality trials. He has received the Linacre Medal of the Royal College of Physicians and gave the Inaugural Michael L. Pollock Memorial Lecture of the American Heart Association. In 2010, Dr. Coats was appointed the Norwich Research Park Professor-at-Large, University of East Anglia.

Mark Maciejewski, 56, is president and chief executive officer of Sinnomedical, L.L.C., a China-based company creating strategic partnerships with U.S. companies to transfer new medical technologies to China. He also serves as senior vice president of international investments at the National Technology Enterprise Co. of the Kuwait Investment Authority. Prior to that, he founded numerous medical companies, was a managing director of U.S. Surgical-Tyco Healthcare, and served as president and chief executive officer of Angioguard, a company acquired by Cordis in 1999. Mr. Maciejewski holds an M.B.A. from the University of Saint Thomas, an M.S. in biochem­istry from Wright State University, and a biomedical engineering degree from the University of Dayton.

LoneStar Heart Inc.

LoneStar Heart Inc. is developing cardiac restorative therapies for patients with heart failure that harness the heart's ability to repair itself. Based on its integrated cardiomechanical and biomolecular technologies, the privately held company is advanc­ing a broad portfolio of products to restore the failing heart's structure and function in collaboration with the Texas Heart Institute, the UTSW, and a global network of leading clinicians. These products include Algisyl-LVR™, cardiac stem-cell modulators, and cellular and genetic therapies delivered as stand-alone treatments, or in combination with the company's proprietary biopolymer matrix system.

LoneStar Heart's lead product, Algisyl-LVR, is a single-use, self-gelling biopolymer implanted into the heart's left ventricle during surgery. Providing internal tissue support, Algisyl-LVR is aimed at preventing the progression of heart failure and restoring the heart's normal structure and function with a significant improvement in the patient's quality of life. Classified as a medical device, the product is undergoing a randomized controlled clinical study (AUGMENT-HF) in Europe to evaluate its safety and efficacy in patients with advanced heart failure.

 

 


'/>"/>
SOURCE LoneStar Heart Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Arizona Heart: Three Advanced Technology Operating Rooms With State-of-the Art C-arm Solutions
2. BHI Urges People with Heart Disease to Get Their Hearing Checked During American Heart Month
3. Journal of Cardiovascular Electrophysiology Study Shows Promising Single Ablation Procedure Outcomes With HeartLight EAS for Treatment of Atrial Fibrillation
4. HeartWare and Dualis MedTech Announce Agreement to Develop Fully Implantable Ventricular Assist System
5. Boston Scientific Raises Awareness of Heart Disease at Brandon Jennings Invitational
6. Abaxis Animal Health Announces the Addition of a Feline Heartworm Application to the Rapid Diagnostics Product Line
7. FDA Approves Mechanical Cardiac Assist Device for Children With Heart Failure
8. Celladon Corporation Receives FDA Fast Track Designation for Its Investigational Agent MYDICAR® for the Treatment of Heart Failure
9. Flagstaff Medical Center to Use Smart Phones to Extend Care for Heart Patients
10. HeartWare to Present at the Oppenheimer 22nd Annual Healthcare Conference
11. FDA Advisory Panel Recommends Against Approval of Champion® Heart Failure Management System for Patients With Heart Failure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Research and Markets has announced the addition of the ... to their offering. ... World Market for Companion Diagnostics covers the world market for ... report includes the following: , World IVD ... (N. America, EU, ROW), 2015-2020 , World IVD Companion ...
(Date:6/24/2016)... 2016  Arkis BioSciences, a leading innovator in ... durable cerebrospinal fluid treatments, today announced it has ... is led by Innova Memphis, followed by Angel ... investors.  Arkis, new financing will accelerate the commercialization ... release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... 2016 Research and Markets has ... by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), ... Parenteral) - Global Forecast to 2021" report to ... The global pharmaceutical excipients market is projected to reach ... 6.1% in the forecast period 2016 to 2021. ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson ... Recently, he has implemented orthobiologic procedures as a method for treating his patients. ... the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events ... turn to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. ... tools for healthy coping following a traumatic event. , Trauma sufferers tend to feel ...
(Date:6/24/2016)... MIAMI, Fla. (PRWEB) , ... June 24, 2016 , ... ... Florida Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this ... of Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this ...
(Date:6/24/2016)... , ... June 24, 2016 , ... People across the ... Genome magazine’s Code Talker Award, an essay contest in which patients and their families ... to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education ...
(Date:6/24/2016)... ... 24, 2016 , ... Strategic Capital Partners, LLC (SCP) in ... investment capital for emerging technology companies. SCP has delivered investment events and ... more than a million dollars of capital investment for five companies. ...
Breaking Medicine News(10 mins):